SYNEDGEN, INC.
Federal contract awards won by SYNEDGEN, INC. (UEI HX79BD6YQ521), 2022–2024 — public record from USAspending.
Showing awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
3
awards
$21,675,803
total value
2
agencies
Agencies buying from SYNEDGEN, INC.
What SYNEDGEN, INC. sells
Awards
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
Department of Health and Human Services · $18,828,663 · Sep 30, 2024
SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION OR NUCLEAR INJURY"
Department of Defense · $2,297,415 · Sep 20, 2024
AWARD OF SYNEDGEN'S DHA SBIR PHASE III FOLLOW-ON MEDICAL R&D CONTRACT FOR "DEVELOPMENT OF TECHNOLOGIES THAT CONTROL SCAR FORMATION AFTER BURN INJURIES"
Department of Defense · $549,725 · Aug 22, 2022
Researching this competitor? BidCatch doesn't just show you what they won — it sends you the open bids in your trade every morning, before they're awarded. Free for 14 days, then $49.99/month.
Search open bids